( s positive airway pressure (nCPAP) inte...)Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting,Health

s positive airway pressure (nCPAP) intended to treat premature infants at risk for respiratory failure. Premature infants at risk for Respiratory Distress Syndrome (RDS) benefit from both nCPAP and intratracheal instillation of lung surfactants. Administration of aerosolized lung surfactants via nCPAP, may avoid the need for endotracheal intubation. The potential utility of a less-invasive method of delivering lung surfactants to treat premature infants suffering from an array of respiratory disorders has been recognized by the neonatal medical community.

Chrysalis Technologies Aerosol Generation Technology

The Chrysalis Technologies aerosol generation technology is designed to produce high-quality, low velocity aerosols for possible deep lung aerosol delivery. Aerosols are created by pumping the drug formulation through a small, heated capillary, yielding a dense aerosol with a defined particle size. The defined particle size can be readily controlled and adjusted through device modifications. Discovery has a strategic alliance with Chrysalis Technologies (a division of Philip Morris USA) to develop and commercialize aerosolized SRT to address a broad range of serious respiratory conditions. Through this alliance, Discovery gained exclusive rights to Chrysalis' novel aerosol generating technology for use with pulmonary surfactants for all respiratory diseases.

About Discovery Labs

Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery's technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant. Discovery believes that its proprietary SRT pipeline has the potential to advance respiratory medicine and address a variety of respiratory diseases affecting neonatal, pediatric and adult patien
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session